ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.02
0.42%
Dow Jones
42,175.11
0.00%
Gold vs US Dollar
2,665.135
-0.28%
Brent Oil
71.015
0.09%
Bitcoin
65,780.54
0.92%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BeyondSpring Inc (BYSI)

  7. BeyondSpring Inc (BYSI) News

BeyondSpring (BYSI)

BeyondSpring Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BYSI
DateTimeSourceHeadlineSymbolCompany
16/09/202412:00GlobeNewswire Inc.BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024NASDAQ:BYSIBeyondSpring Inc
16/09/202412:00GlobeNewswire Inc.BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024NASDAQ:BYSIBeyondSpring Inc
10/09/202412:00GlobeNewswire Inc.BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory MediciNASDAQ:BYSIBeyondSpring Inc
03/09/202412:00GlobeNewswire Inc.BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, PlinabulinNASDAQ:BYSIBeyondSpring Inc
29/08/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
06/08/202413:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
06/08/202412:00GlobeNewswire Inc.SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology IndicationsNASDAQ:BYSIBeyondSpring Inc
15/07/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BYSIBeyondSpring Inc
12/06/202422:11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BYSIBeyondSpring Inc
12/06/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
12/06/202413:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BYSIBeyondSpring Inc
16/05/202413:00GlobeNewswire Inc.BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
03/05/202412:00GlobeNewswire Inc.BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
29/04/202422:30GlobeNewswire Inc.BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsNASDAQ:BYSIBeyondSpring Inc
29/04/202422:30GlobeNewswire Inc.BeyondSpring Files 2023 Annual Report on Form 20-FNASDAQ:BYSIBeyondSpring Inc
25/03/202411:00GlobeNewswire Inc.BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerNASDAQ:BYSIBeyondSpring Inc
26/02/202413:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
26/02/202413:00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsNASDAQ:BYSIBeyondSpring Inc
14/02/202421:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BYSIBeyondSpring Inc
02/02/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
16/01/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
10/01/202420:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
10/01/202420:00GlobeNewswire Inc.BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KNASDAQ:BYSIBeyondSpring Inc
18/12/202321:31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
18/12/202321:30GlobeNewswire Inc.BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:BYSIBeyondSpring Inc
07/11/202312:00GlobeNewswire Inc.BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 InhibitorsNASDAQ:BYSIBeyondSpring Inc
31/10/202312:00GlobeNewswire Inc.BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsNASDAQ:BYSIBeyondSpring Inc
30/10/202312:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
30/10/202312:00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:BYSIBeyondSpring Inc
26/10/202313:30GlobeNewswire Inc.SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumNASDAQ:BYSIBeyondSpring Inc
 Showing the most relevant articles for your search:NASDAQ:BYSI

Your Recent History

LSE
43NP
Lloyds Bk. 24
COIN
TERCBTC
TRONEuropeRewardCoin
COIN
JPKCBTC
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved